Le Lézard
Classified in: Health
Subject: RCL

Olympia Pharmacy Issues Voluntary Nationwide Recall of Seven Compounded Products due to Being Out-Of-Specification


ORLANDO, Fla., March 11, 2022 /PRNewswire-PRWeb/ -- Olympia Pharmacy is voluntarily recalling 11 specific lots of Trimix Formulas F-9, T-105, SB-4, Sermorelin, Sincalide, Hydroxocobalamin, and NAD, compounded injectables to the consumer level. These compounded products were found to be out-of-specification.

Risk Statement: Administration of subpotent Hydroxocobalamin in infants, pregnant/breastfeeding women, and elderly populations are at risk for vitamin B12 deficiency and there is a reasonable probability they could experience adverse events including muscle weakness, neurological peripheral neuropathic numbness or pain, vision loss, and psychiatric disorders (depression, memory loss). Additionally, injectable compounded products, found to contain more or less drug product than the labeled strength or which reconstitute at a different rate than intended, may result in either too much or too little medication being administered. This could result in lower-than-expected effectiveness of the drug or unintended adverse side effects.

Olympia Pharmacy has not received any reports or concerns from patients relating to the safety of the recalled sterile compounded products, and no patients have reported any adverse events attributed to any of the recalled sterile compounded products.

The compounded products being recalled are typically prescribed by medical professionals for age management, erectile dysfunction, vitamin deficiencies, and for diagnostic imaging of the gallbladder. The affected lots include the following lot numbers and expiration dates listed below. The product can be identified by reading the lot number in the black strike zone of the label and was distributed to patients and health clinics.

Drug Vial Size Lot Best Use Date
NAD 500mg vial C41008 3/8/22
NAD 500mg vial D24005 4/5/22
Sincalide 5 mcg vial D24001 4/1/22
Trimix Formula F9 10 ml vial D41C19 4/19/22
Sermorelin Acetate 9 mg 9 mg vial D44026 4/26/22
Sermorelin Acetate 9 mg 9 mg vial F42104 6/4/22
Trimix T-105, 5 ml vial E41F10 5/10/22
Trimix T-105, 10 ml vial E41G10 5/10/22
Trimix SB-4 5 ml vial E41C18 5/18/22
Trimix SB-4 10 ml vial E41D18 5/18/22
Hydroxocobalamin 1mg/ml 30 ml vial E47025 5/21/22

Olympia Pharmacy is notifying its customers by mail and is arranging for return and replacement of all recalled compounded products. Patients and health clinics that have any of the listed compounded products which are being recalled should stop using and return to Olympia Pharmacy.

Consumers with questions regarding this recall can contact Olympia Pharmacy by phone at 407-250-4000 or e-mail [email protected] Monday through Friday from 9 am to 6 pm Eastern Standard Time.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Media Contact

Recall Coordinator, Olympia Pharmacy, 1 4072504000, [email protected]

 

SOURCE Olympia Pharmacy


These press releases may also interest you

at 01:50
SHL Telemedicine Ltd. ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is thrilled to announce that it recently officially launched it's SmartHeart® membership program in the US. This...

at 01:30
XRP Healthcare proudly announces its sponsorship of the upcoming Ehlers-Danlos Society event in Philadelphia this July 17th ? 21st....

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The...

at 00:00
Author Kory L. Wilson and his family have experienced the benefits of information he shares in Home Remedies: A Guidebook To Breaking Away From Big Pharma ($15.99, paperback, 9781662896668; $6.99, e-book, 9781662896675). For years, I have collected...

15 mai 2024
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates.Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3...

15 mai 2024
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...



News published on and distributed by: